Positive Ph 2 Final Efficacy Results from Investigator-Sponsored TASKIN Trial in Refractory Metastatic CRC Announced
Professor François Ghiringhelli, M.D., Ph.D., Principal Investigator of the TASKIN study and Director of the Oncology Department at Centre Georges-François Leclerc, commented, “Patients with refractory metastatic colorectal cancer face severe therapeutic limitations and poor survival outcomes. Meeting our pre-specified primary milestone provides compelling evidence that targeting IL-1α plays a meaningful role in tumor biology. Most striking is the magnitude of benefit observed in right-sided colorectal cancers, which has been a historically aggressive disease subset with high unmet medical need. The alignment between this pronounced clinical survival advantage and elevated basal IL-1α tumor expression offers a clear biological rationale for this therapy.”
Share:
More News
Taiho Oncology, Inc. completed a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for zipalertinib in combination with platinum-based chemotherapy for the treatment of patients with previously untreated, locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20
“This collaboration reflects our conviction that atebimetinib has the potential to become an essential backbone therapy in a broad range of combinations across MAPK-driven cancers,” said Ben Zeskind, Immuneering CEO and co-founder. “Atebimetinib’s unique tolerability profile and broad activity make it well suited to combine with a wide range of
“These final updated results provide continued evidence of the potential for γδ T cell therapies to drive activity and improve outcomes for patients,” said William Ho, CEO and co-founder of IN8bio. “The clinical outcomes and observed activity are supported by our correlative analysis, including histopathology, demonstrating the expansion and persistence
“Patients with RAS-mutated mCRC have no first-line therapies specifically approved for their disease, and Fast Track designation reflects the potential of onvansertib to address this serious unmet need,” said Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology. “Our randomized Phase 2 data give us confidence that onvansertib